Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 307

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline

Open access
Visvanathan, Kala, Hurley, Patricia, Bantug, Elissa, Brown, Powel, Col, Nananda F., Cuzick, Jack, Davidson, Nancy E., DeCensi, Andrea, Fabian, Carol, Ford, Leslie, Garber, Judy, Katapodi, Maria, Kramer, Barnett, Morrow, Monica, Parker, Barbara, Runowicz, Carolyn, Vogel, Victor G., Wade, James L., Lippman, Scott M.·2013·Journal of Clinical Oncology

Abstract

Purpose: To update the 2009 American Society of Clinical Oncology guideline on pharmacologic interventions for breast cancer (BC) risk reduction. Methods: A systematic review of randomized controlled trials and meta-analyses published from June 2007 through June 2012 was completed using MEDLINE and Cochrane Collaboration Library. Primary outcome of interest was BC incidence (invasive and noninvasive). Secondary outcomes included BC mortality, adverse events, and net health benefits. Guideline recommendations were revised based on an Update Committee's review of the literature. Results: Nineteen articles met the selection criteria. Six chemoprevention agents were identified: tamoxifen, raloxifene, arzoxifene, lasofoxifene, exemestane, and anastrozole. Recommendations: In women at increased risk of BC age ≥ 35 years, tamoxifen (20 mg per day for 5 years) should be discussed as an option to reduce the risk of estrogen receptor (ER) –positive BC. In postmenopausal women, raloxifene (60 mg per day for 5 years) and exemestane (25 mg per day for 5 years) should also be discussed as options for BC risk reduction. Those at increased BC risk are defined as individuals with a 5-year projected absolute risk of BC ≥ 1.66% (based on the National Cancer Institute BC Risk Assessment Tool or an equivalent measure) or women diagnosed with lobular carcinoma in situ. Use of other selective ER modulators or other aromatase inhibitors to lower BC risk is not recommended outside of a clinical trial. Health care providers are encouraged to discuss the option of chemoprevention among women at increased BC risk. The discussion should include the specific risks and benefits associated with each chemopreventive agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.49.3122

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 307

Metadata

Authors
Visvanathan, K., Hurley, P., Bantug, E., Brown, P., Col, N. F., Cuzick, J., Davidson, N. E., DeCensi, A., Fabian, C., Ford, L., Garber, J., Katapodi, M., Kramer, B., Morrow, M., Parker, B., Runowicz, C., Vogel, V. G., Wade, J. L., & Lippman, S. M.
Venue
Journal of Clinical Oncology
Published
2013-08-10
Volume
31
Issue
23
Pages
2942-2962
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2119890674
Cited by
307
References
62
FWCI
28.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline. https://app.cochat.ai/papers/10.1200/jco.2013.49.3122
The paper
Visvanathan, K., Hurley, P., Bantug, E., Brown, P., Col, N. F., Cuzick, J., Davidson, N. E., DeCensi, A., Fabian, C., Ford, L., Garber, J., Katapodi, M., Kramer, B., Morrow, M., Parker, B., Runowicz, C., Vogel, V. G., Wade, J. L., & Lippman, S. M. (2013). Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.49.3122

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.